|
EP2224961A1
(en)
*
|
2007-11-26 |
2010-09-08 |
The Research Foundation of the State University of New York |
Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells
|
|
WO2010044894A1
(en)
|
2008-10-15 |
2010-04-22 |
4S3 Bioscience Inc. |
Methods and compositions for treatment of myotonic dystrophy
|
|
US9155801B2
(en)
|
2009-05-28 |
2015-10-13 |
The United States Government As Represented By The Department Of Veterans Affairs |
Amino acid sequences which enhance peptide conjugate solubility
|
|
AU2010260145B2
(en)
|
2009-06-15 |
2015-08-20 |
Valerion Therapeutics, Llc |
Methods and compositions for treatment of Myotubular Myopathy using chimeric polypeptides comprising myotubularin 1 (MTM1) polypeptides
|
|
JP6178785B2
(ja)
*
|
2011-04-01 |
2017-08-09 |
イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ |
細胞浸透性抗ｄｎａ抗体およびｄｎａ修復を阻害するためのその使用
|
|
CA2832184A1
(en)
*
|
2011-04-07 |
2012-10-11 |
Memorial Sloan Kettering Cancer Center |
Anti-tumor antibody-tumor suppressor fusion protein compositions and methods of use for the treatment of cancer
|
|
CA2907072A1
(en)
|
2012-03-16 |
2013-09-19 |
Valerion Therapeutics, Llc |
Antisense conjugates for decreasing expression of dmpk
|
|
US12195550B2
(en)
*
|
2012-03-30 |
2025-01-14 |
The United States Of America As Represented By The Department Of Veterans Affairs |
Targeting intracellular target-binding determinants with intracellular antibodies
|
|
US9283272B2
(en)
*
|
2012-03-30 |
2016-03-15 |
The United States Of America As Represented By The Department Of Veterans Affairs |
Targeting intracellular target-binding determinants with intracellular antibodies
|
|
WO2013177428A1
(en)
*
|
2012-05-23 |
2013-11-28 |
Valerion Therapeutics, Inc. |
Methods for increasing muscle contractility
|
|
AU2014218854B2
(en)
|
2013-02-20 |
2019-01-24 |
Valerion Therapeutics, Llc |
Methods and compositions for treatment of Pompe disease
|
|
AU2015204446A1
(en)
|
2014-01-13 |
2016-07-14 |
Valerion Therapeutics, Llc |
Internalizing moieties
|
|
US10040867B2
(en)
|
2014-03-04 |
2018-08-07 |
Yale University |
Cell penetrating anti-guanosine antibody based therapy for cancers with Ras mutations
|
|
US10238742B2
(en)
|
2014-06-25 |
2019-03-26 |
Yale University |
Cell penetrating nucleolytic antibody based cancer therapy
|
|
CA2995673A1
(en)
|
2014-08-27 |
2016-03-03 |
Valerion Therapeutics, Llc |
Internalizing moieties for treatment of cancer
|
|
CN109069644B
(zh)
|
2015-10-08 |
2022-10-28 |
犹他大学研究基金会 |
用于预防或治疗癌症的方法和组合物
|
|
WO2017189483A1
(en)
|
2016-04-25 |
2017-11-02 |
The Johns Hopkins University |
Znt8 assays for drug development and pharmaceutical compositions
|
|
WO2017218824A1
(en)
|
2016-06-15 |
2017-12-21 |
Yale University |
Anti-guanosine antibody as a molecular delivery vehicle
|
|
EP3471777A1
(en)
|
2016-06-15 |
2019-04-24 |
Yale University |
Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors
|
|
EP3652540A4
(en)
|
2017-07-12 |
2021-04-07 |
The Johns Hopkins University |
PROTEOLIPOSOME-BASED ZNT8 SELF-ANTIGEN FOR DIAGNOSIS OF TYPE 1 DIABETES
|
|
WO2019152806A1
(en)
*
|
2018-02-01 |
2019-08-08 |
Yale University |
Compositions and methods for enhancing nuclear translocation
|
|
US12239720B2
(en)
|
2018-04-06 |
2025-03-04 |
Oncolyze, Inc. |
Compositions for use in lysis of selective cancer cells
|
|
WO2020037174A1
(en)
|
2018-08-16 |
2020-02-20 |
The Johns Hopkins University |
Antibodies to human znt8
|
|
EP3844287B1
(en)
|
2018-08-31 |
2024-05-22 |
Yale University |
Compositions and methods for enhancing donor oligonucleotide-based gene editing
|
|
WO2021042060A1
(en)
|
2019-08-30 |
2021-03-04 |
Yale University |
Compositions and methods for delivery of nucleic acids to cells
|
|
US12366570B2
(en)
|
2019-10-01 |
2025-07-22 |
The Johns Hopkins University |
Cell-based ZNT8 assay
|
|
CA3228876A1
(en)
*
|
2021-08-20 |
2023-02-23 |
Dax Fu |
Cell-surface antibody to a specific biomarker of pancreatic beta-cells
|